Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children.

Giacomet V, Mora S, Martelli L, Merlo M, Sciannamblo M, Viganò A.

J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):448-50.

PMID:
16280700
2.

Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function.

Rosso R, Nasi M, Di Biagio A, Repetto E, Dentone C, Pinti M, Nemes E, Ferraresi R, Mussini C, Esposito R, Viscoli C, Cossarizza A.

Pediatr Infect Dis J. 2008 Jan;27(1):17-21.

PMID:
18162932
3.

Tenofovir disoproxil fumarate and bone mineral density: a 60-month longitudinal study in a cohort of HIV-infected youths.

Viganò A, Zuccotti GV, Puzzovio M, Pivetti V, Zamproni I, Cerini C, Fabiano V, Giacomet V, Mora S.

Antivir Ther. 2010;15(7):1053-8. doi: 10.3851/IMP1650.

PMID:
21041922
4.

The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.

Milinkovic A, Martinez E, López S, de Lazzari E, Miró O, Vidal S, Blanco JL, Garrabou G, Laguno M, Arnaiz JA, Leon A, Larrousse M, Lonca M, Mallolas J, Gatell JM.

Antivir Ther. 2007;12(3):407-15.

PMID:
17591031
5.

In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers.

Viganò A, Mora S, Giacomet V, Stucchi S, Manfredini V, Gabiano C, Salvini F, Cellini M, Tamburrini E, Puzzovio M, Zuccotti GV.

Antivir Ther. 2011;16(8):1259-66. doi: 10.3851/IMP1909.

PMID:
22155907
6.

Predictors of bone mineral density in human immunodeficiency virus-1 infected children.

Jacobson DL, Spiegelman D, Duggan C, Weinberg GA, Bechard L, Furuta L, Nicchitta J, Gorbach SL, Miller TL.

J Pediatr Gastroenterol Nutr. 2005 Sep;41(3):339-46.

PMID:
16131991
7.

Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.

Rey D, Krebs M, Partisani M, Hess G, Cheneau C, Priester M, Bernard-Henry C, de Mautort E, Lang JM.

J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):530-4.

PMID:
17057610
8.

Metabolic benefits of switching to tenofovir/lamivudine after long-term use of stavudine/lamivudine in NNRTI-based antiretroviral regimens: a prospective study.

Manosuthi W, Lueangniyomkul A, Mankatitham W, Chimsuntorn S, Tantanathip P, Thongyen S, Suntisuklappon B, Nilkamhang S, Sungkanuparph S.

J Infect. 2011 May;62(5):406-9. doi: 10.1016/j.jinf.2011.02.012. Epub 2011 Mar 5. No abstract available.

PMID:
21382413
9.

Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study.

Fux CA, Rauch A, Simcock M, Bucher HC, Hirschel B, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Elzi L, Furrer H; Swiss HIV Cohort Study.

Antivir Ther. 2008;13(8):1077-82.

PMID:
19195333
10.

Improvement of dyslipidemia during different HAART regimens: tenofovir- versus stavudine-containing antiretroviral combinations.

Manfredi R.

Clin Infect Dis. 2006 May 1;42(9):1345-7; author reply 1347-8. No abstract available.

PMID:
16586399
11.

Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy.

Côté HC, Magil AB, Harris M, Scarth BJ, Gadawski I, Wang N, Yu E, Yip B, Zalunardo N, Werb R, Hogg R, Harrigan PR, Montaner JS.

Antivir Ther. 2006;11(1):79-86.

PMID:
16518963
12.

Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy.

Mora S, Sala N, Bricalli D, Zuin G, Chiumello G, Viganò A.

AIDS. 2001 Sep 28;15(14):1823-9.

PMID:
11579244
13.

Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.

Antinori A, Trotta MP, Nasta P, Bini T, Bonora S, Castagna A, Zaccarelli M, Quirino T, Landonio S, Merli S, Tozzi V, Di Perri G, Andreoni M, Perno CF, Carosi G.

Antivir Ther. 2006;11(2):233-43.

PMID:
16640104
14.
15.

Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.

Gafni RI, Hazra R, Reynolds JC, Maldarelli F, Tullio AN, DeCarlo E, Worrell CJ, Flaherty JF, Yale K, Kearney BP, Zeichner SL.

Pediatrics. 2006 Sep;118(3):e711-8. Epub 2006 Aug 21.

PMID:
16923923
16.

[Decreased bone mineral density in HIV-infected children receiving highly active antiretroviral therapy].

Rojo Conejo P, Ramos Amador JT, García Piñar L, Ruano Fajardo C, Sánchez Granados JM, González Tomé MI, Ruiz Contreras J.

An Pediatr (Barc). 2004 Mar;60(3):249-53. Spanish.

17.

Tenofovir-associated severe bone pain: I cannot walk!

Jhaveri MA, Mawad HW, Thornton AC, Mullen NW, Greenberg RN.

J Int Assoc Physicians AIDS Care (Chic). 2010 Sep-Oct;9(5):328-34. doi: 10.1177/1545109710376595.

PMID:
20923957
18.

Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir.

Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez-Novoa S, Solera C, Medrano J, Rivas P, Albalater M, Blanco F, Moreno V, Vispo E, Soriano V.

AIDS. 2009 Mar 27;23(6):689-96. doi: 10.1097/QAD.0b013e3283262a64.

PMID:
19262355
19.

Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy.

Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J.

AIDS. 2003 Sep 5;17(13):1917-23.

PMID:
12960824
20.

Adverse effects of tenofovir use in HIV-infected pregnant women and their infants.

Nurutdinova D, Onen NF, Hayes E, Mondy K, Overton ET.

Ann Pharmacother. 2008 Nov;42(11):1581-5. doi: 10.1345/aph.1L083. Epub 2008 Oct 28.

PMID:
18957630

Supplemental Content

Support Center